title: Cocaine sensitization prevents the hypolocomotor effects of high but not low doses of PD 128,907.
abstract: In this study we examined the effects of the preferential dopamine D3 receptor agonist S(+)-(4aR,10bR)-3,4,4a,10b-tetrahydro-4-propyl-2H,5H-[1]b enzopyrano-[4,3-b]-1,4-oxazin-9-ol (PD 128,907) on locomotion in mice sensitized to cocaine. In mice repeatedly treated with saline, PD 128,907 induced hypoactivity over a wide dose range (0.01-40 mg/kg); however, after repeated treatment with 40 mg/kg cocaine, higher doses of PD 128,907 (2.5-40 mg/kg) no longer induced hypoactivity whereas the effects of lower doses (0.01-0.16 mg/kg) were not altered. Because lower doses of PD 128,907 are thought to induce hypoactivity via activation of dopamine D3 receptors, the present data suggest that, under conditions where cocaine induces marked sensitization to its locomotor effects, the sensitivity of these receptors is not altered. In contrast, because higher doses of PD 128,907 can activate dopamine D2 receptors, it is conceivable that apparent cross-sensitization to its dopamine D2 receptor agonist properties is responsible for the lack of hypolocomotor effects at high doses. Overall, the results indicate that altered dopamine D3 receptor sensitivity does not play an important role in the expression of cocaine-induced sensitization.
authors.affiliation: Centre de Recherche Pierre Fabre, Castres, France. eric.prinssen@pierre-fabre.com
authors.forename: E P
authors.initials: EP
authors.lastname: Prinssen
authors.forename: W
authors.initials: W
authors.lastname: Koek
authors.forename: M S
authors.initials: MS
authors.lastname: Kleven
mesh_terms: D000818:Animals; D001578:Benzopyrans / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D003042:Cocaine / Q000008:administration & dosage / Q000494:pharmacology*; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000494:pharmacology*; D018765:Dopamine Uptake Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009043:Motor Activity / Q000187:drug effects*; D010078:Oxazines / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D017448:Receptors, Dopamine D2 / Q000187:drug effects; D050637:Receptors, Dopamine D3
chemical_list: D001578:Benzopyrans; D018491:Dopamine Agonists; D018765:Dopamine Uptake Inhibitors; C493594:Drd3 protein, mouse; D010078:Oxazines; D017448:Receptors, Dopamine D2; D050637:Receptors, Dopamine D3; C062458:3,4,4a,10b-tetrahydro-4-propyl-2H,5H-(1)benzopyrano(4,3-b)-1,4-oxazin-9-ol; D003042:Cocaine